GSK699

Catalog No. :
ACFFVF191
CAS No. :
2260944-68-9
Molecular Formula :
C45H51BrN8O7
Molecular Weight :
895.86

IUPAC Name:4-((3R,5R)-5-((5-bromo-1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)amino)-1-methylpiperidin-3-yl)-N-(3-((4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)phenyl)(methyl)amino)propyl)-N-methylbenzamide

GSK699 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameGSK699
IUPAC Name4-((3R,5R)-5-((5-bromo-1-methyl-6-oxo-1,6-dihydropyridazin-4-yl)amino)-1-methylpiperidin-3-yl)-N-(3-((4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)propyl)phenyl)(methyl)amino)propyl)-N-methylbenzamide
Molecular FormulaC45H51BrN8O7
Molecular Weight895.86
SMILESO=C1C2=C(OCCCC3=CC=C(C=C3)N(C)CCCN(C)C(C4=CC=C([C@@]5([H])C[C@H](CN(C5)C)NC6=C(C(N(N=C6)C)=O)Br)C=C4)=O)C=CC=C2C(N1C7C(NC(CC7)=O)=O)=O
InChI KeySARLMRHJAJBYBI-CIDUPMPKSA-N
SynonymGSK 699);GSK699 (GSK-699;Benzamide, 4-[(3R,5R)-5-[(5-bromo-1,6-dihydro-1-methyl-6-oxo-4-pyridazinyl)amino]-1-methyl-3-piperidinyl]-N-[3-[[4-[3-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]propyl]phenyl]methylamino]propyl]-N-methyl-
CAS No.2260944-68-9

Synthetic Route by SureRoute

1. ACFFVF191 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFFVF191 route product structure diagram
    ACFFVF1912260944-68-9
Inquiry

2. ACFFVF191 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFFVF191 route product structure diagram
    ACFFVF1912260944-68-9
Inquiry

Comments (0)